Gastrointestinal OTC Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Drug Class (Laxatives, Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal, Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel Anti-Inflammatory, Anti-Emetics), By Indication (Gastroesophageal Reflux Disease or Heartburn, Constipation
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationGastrointestinal OTC Drugs Market – Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented by Drug Class (Laxatives, Gastrointestinal Cancer Treatments, Gastric Acid Reducers, Anti-Diarrheal, Proton Pump Inhibitors, H2 Inhibitors, Gastric Acid Neutralizers, Bowel Anti-Inflammatory, Anti-Emetics), By Indication (Gastroesophageal Reflux Disease or Heartburn, Constipation
| Forecast Period | 2024-2028 |
| Market Size (2022) | 31 billion |
| CAGR (2023-2028) | 3.80 % |
| Fastest Growing Segment | Retail Pharmacies Segment |
| Largest Market | North America |
Market Overview
Global Gastrointestinal OTC Drugs Market has valued at USD 31 billion in 2022 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 3.80% through 2028.
The global aging population is more susceptible to gastrointestinal issues. As people age, they are more likely to experience digestive problems, which increases the need for OTC gastrointestinal remedies. Increasing awareness among consumers about gastrointestinal health and related issues encourages them to seek OTC solutions for common digestive problems. Educational campaigns and information dissemination contribute to this awareness.
Key Market Drivers
Increasing Demand of Probiotics and Digestive Supplements
Probiotics are live beneficial bacteria that can help maintain a healthy balance of gut microorganisms. Digestive supplements may contain fiber, enzymes, or other ingredients that support digestive health. Consumers are increasingly interested in maintaining a healthy gut microbiome, and both probiotics and digestive supplements are perceived as proactive measures to achieve this. As a result, these products drive demand for OTC drugs by addressing and preventing gastrointestinal issues. Probiotics and certain digestive supplements are used to manage specific gastrointestinal conditions, such as irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). These conditions often require ongoing management, and consumers may turn to OTC drugs for symptom relief in addition to their regular use of probiotics and supplements. Many individuals take probiotics and digestive supplements as part of their daily wellness routine, even when they don't have specific digestive complaints. This preventive approach to gut health may reduce the risk of developing gastrointestinal issues and, in turn, decrease the need for more intensive OTC treatments in the future.
Consumers often use probiotics, digestive supplements, and OTC drugs in combination to address various gastrointestinal concerns. For example, they may take probiotics regularly but use OTC antacids or laxatives as needed for specific symptoms. This complementary usage pattern boosts the demand for both types of products. Increased consumer education and awareness campaigns about the benefits of probiotics and digestive supplements have contributed to their popularity. As consumers become more informed about these products, they are more likely to incorporate them into their daily routines and seek OTC drugs when necessary. The market for probiotics and digestive supplements continues to evolve, with companies introducing new formulations and delivery methods that cater to consumer preferences. For instance, chewable probiotic tablets and gummies are popular options for those who dislike capsules or pills. Probiotics and digestive supplements are widely found at in retail channels, such as pharmacies, drug retailers, supermarkets, and online platforms. This accessibility encourages consumers to explore these products and, if needed, purchase complementary OTC drugs during the same shopping trip. This factor will help in the development of the
Innovation in Formulations
The development of new and improved formulations enhances the effectiveness, convenience, and appeal of these products, contributing to increased consumer demand.
Some formulations are designed to minimize common side effects associated with gastrointestinal drugs, such as constipation or upset stomach. These formulations are well-received by consumers seeking relief without adverse reactions. Innovations in formulations may involve the use of natural and herbal ingredients, which appeal to consumers looking for holistic and gentle approaches to managing gastrointestinal issues. Formulations that combine traditional gastrointestinal drugs with probiotics or prebiotics appeal to consumers seeking comprehensive digestive health solutions. These integrated products address both symptom relief and gut health maintenance. Some formulations are designed to address multiple gastrointestinal symptoms simultaneously. For example, OTC products for irritable bowel syndrome (IBS) may contain a combination of ingredients to target bloating, diarrhea, and abdominal pain. Innovative packaging, such as individually wrapped doses or user-friendly dispensers, enhances product convenience and portability. Consumers are more likely to choose products that are easy to carry and use on the go. Companies often promote the benefits of their innovative formulations through marketing campaigns and consumer education efforts. This raises awareness and drives consumer interest in these products. This factor will pace up the demand of the
Rising Demand of Non-Invasive Treatment Options
Consumers often prefer non-invasive or minimally invasive approaches to managing common gastrointestinal issues before considering more invasive medical interventions.
Many non-invasive OTC drugs have a lower risk of significant side effects compared to prescription medications, which may have more potent or systemic effects. Consumers are more comfortable with OTC options that typically have milder side effects. Non-invasive treatments allow individuals to continue their daily activities with minimal disruption. This is particularly important for those managing chronic gastrointestinal conditions like acid reflux or irritable bowel syndrome (IBS). Some individuals use non-invasive OTC drugs preventatively. For example, they may take antacids or probiotics regularly to prevent the onset of symptoms, reducing the need for reactive treatment. OTC drugs are readily found at without the need for a healthcare provider's prescription or consultation, making them accessible to consumers who prefer to self-diagnose and self-medicate. Consumer education initiatives and the availability of information through product labeling, package inserts, and online resources encourage individuals to explore non-invasive OTC options for managing gastrointestinal symptoms. Regulatory agencies often evaluate and approve OTC drugs for safety and efficacy. These approvals provide consumers with confidence in the quality and effectiveness of non-invasive treatments. This factor will accelerate the demand of the Global Gastrointestinal OTC Drugs Market.
Key Market Challenges
Generic Competition
Generic gastrointestinal OTC drugs typically cost less than their branded counterparts. This price competition can lead to lower profit margins for pharmaceutical companies that market branded OTC drugs, as consumers often opt for more affordable generic options. Some gastrointestinal OTC drugs have been on the market for a long time, and they may have multiple generic equivalents. This can lead to market saturation, with numerous generic products vying for a share of the market. When a branded OTC drug's patent expires, it opens the door for generic manufacturers to enter the market with their versions of the drug. As a result, the branded drug may experience a decline in market share. The presence of generic competitors can put pressure on branded OTC drug manufacturers to lower their prices, reducing their profitability. They may need to engage in price wars to maintain their market share. Generic drugs are generally perceived as cost-effective alternatives to branded drugs. This perception can lead consumers to switch from branded to generic OTC drugs when found at, contributing to the challenges faced by branded manufacturers. Generic drugs must meet regulatory standards for safety, efficacy, and quality, just like branded drugs. Branded manufacturers may face increased scrutiny and competition from generic companies that adhere to these standards. Branded OTC drug manufacturers often invest heavily in marketing and promotional efforts to differentiate their products. However, generic competitors may not invest as much in marketing, relying on price advantage instead.
Market Saturation
Market saturation occurs when there is an abundance of similar products within a specific product category, resulting in intense competition and limited opportunities for growth.
Key Market Trends
Natural and Herbal Remedies
Many consumers prefer natural and herbal remedies for gastrointestinal problems because they perceive them as gentler and having fewer side effects compared to synthetic drugs. A growing awareness of holistic health and wellness has encouraged individuals to seek natural and herbal solutions to address the root causes of gastrointestinal issues rather than just managing symptoms. Natural and herbal OTC products often contain plant-based ingredients known for their digestive benefits. Examples include ginger, peppermint, chamomile, aloe vera, and licorice. Probiotic supplements and prebiotic fiber sources have gained popularity for pro
Segmental Insights
Drug Class Insights
In 2022, the Global Gastrointestinal OTC Drugs Market largest share was held by Gastric Acid Reducers segment and is predicted to continue expanding over the coming years.
Indication Insights
In 2022, the Global Gastrointestinal OTC Drugs Market largest share was held by Constipation segment and is predicted to continue expanding over the coming years.
End-User Insights
In 2022, the Global Gastrointestinal OTC Drugs Market largest share was held by retail Pharmacies segment in the forecast period and is predicted to continue expanding over the coming years. Retail pharmacies are easily accessible to consumers in urban, suburban, and rural areas. They provide a convenient and widely recognized location for consumers to purchase OTC drugs, including gastrointestinal remedies. Consumers often trust the expertise of pharmacists in retail pharmacies, who can provide guidance and recommendations for OTC products, including those for gastrointestinal issues. This trust in the healthcare professional's advice can influence purchasing decisions. Retail pharmacies typically offer a broad range of OTC drugs, including various brands and formulations of gastrointestinal products. This diversity allows consumers to choose products that suit their preferences and needs. Many consumers are familiar with the layout and operation of retail pharmacies, making them a convenient option for purchasing OTC drugs. Consumers can visit these retailers during regular shopping trips.
Regional Insights
The North America region dominates the Global Gastrointestinal OTC Drugs Market in 2022. North America, particularly the United States, has one of the highest healthcare expenditures in the world. This substantial spending capacity allows consumers in the region to afford OTC medications, including gastrointestinal drugs. North America has a significant aging population, and elderly individuals are more prone to gastrointestinal issues. As people age, they may require OTC drugs for conditions like heartburn, constipation, and indigestion, which boosts the demand for gastrointestinal OTC drugs.
Recent Developments
- In May 2020, As the firstbrand-new medication expressly authorised as a fourth-line therapy for advancedgastrointestinal stromal tumour (GIST), a form of tumour that develops in thedigestive system, the U.S. Food and Drug Administration approved Qinlock(ripretinib) tablets. Adult patients who have already undergone therapy withthree or more kinase inhibitor treatments, including imatinib, are eligible forQinlock. The FDA authorised Qinlock based on thefindings of an international, multi-center, randomised, double-blind,placebo-controlled clinical study that included 129 patients with advanced GISTwho had previously been treated with imatinib, sunitinib, and regorafenib,three additional FDA-licenced targeted treatments. To ascertain whetherprogression free survival (PFS), which measures the amount of time between thestart of treatment in a clinical trial and the growth of the cancer or death,was longer in the Qinlock group than the placebo group, the trial comparedpatients who were randomly assigned to receive Qinlock to patients who wererandomly assigned to receive a placebo.
- In July 2020, as part ofits Gastrointestinal (GI) portfolio, Takeda India, a subsidiary of the Japanesepharmaceutical giant Takeda Pharmaceutical Company, announced the launch of itspopular biologic medicine Vedolizumab in India. Chronic inflammatory bowelillnesses (IBD) such Ulcerative Colitis and Crohn's Disease are treated withvedolizumab, which is marketed as Kynteles in India. According to themanufacturer, Kynteles has demonstrated excellent safety and effectivenessoutcomes when treating individuals with mild to moderate inflammatory boweldisease (IBD).
- In November 2022, Exocrinepancreatic insufficiency (EPI), which is linked to cystic fibrosis and chronicpancreatitis, will be treated with First Wave Biopharma's drug in a phase 2study. An oral recombinant lipase enzyme called adrulipase from First Wave isintended to break down fat molecules in EPI patients' digestive tracts so thatthe molecules may be absorbed as nutrients.
Key Market Players
- Mylan N.V
- Sandoz AG
- Johnson &Johnson Services, Inc.
- Sun PharmaceuticalsIndustries Limited
- Teva PharmaceuticalsIndustries Ltd.
- Zydus Life scienceLtd.
- Sanofi SA
- Bayer AG
- Pfizer Inc.
- GlaxoSmithKline Plc.
| By Drug Class | By Indication | By End-User | By Region | By Region |
|
|
|
|
|
Report Scope
In this report, the Global Gastrointestinal OTC Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below
- Gastrointestinal OTC Drugs Market, By Drug Class
o
o
o
o
o
o
o
o
o
- Gastrointestinal OTC Drugs Market, By Indication
o
o
o
o
- Gastrointestinal OTC Drugs Market, By End-User
o
o
o
o
- Global Gastrointestinal OTC Drugs Market, By region
North America
Asia-Pacific
Europe
South America
Middle East & Africa
Competitive Landscape
Company Profiles
found at Customizations
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Global Gastrointestinal OTC Drugs Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at sales@techsciresearch.com
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy